Presentations at CRYO2016 Feature CPSI’s FrostBite GI Cancer Cryoablation Platform

Studies focused on the FrostBite device platform and cancer response to cryoablation highlight the potential use of this next generation technology for the treatment of pancreatic and esophageal cancer.

August 3, 2016 – Owego, NY – The need for the development of new devices and strategies to treat cancer was front and center at this year’s annual meeting of the Society for Cryobiology held in Ottawa, Canada in the session “Cool Developments in Cryomedicine”. This 2 part, 4-hour session featured 9 presentations focused on new developments in the use of cryo for disease treatment. As part of the session, CPSI scientists presented three studies focusing on molecular studies and device development in the areas of prostate (John M. Baust, Ph.D., CPSI President), pancreatic (Anthony Robilotto, MS., CPSI Engineer) and esophageal cancer (Kristi Snyder, Ph.D., Principal Scientist). Central to these studies was the incorporation of several of CPSI’s new device technologies including the PSN cryoablation device, FrostBite cryoablation catheter and EsoAblate cryoprobe. The FrostBite and EsoAblate cryoprobes are under development for the minimally invasive endoscopic based treatment of pancreatic and esophageal cancer, among other gastrointestinal cancers. The studies included discussion of cancer cell response to freezing, device design and characterization analysis as well as data from a series of studies conducted using tissue engineered pancreas and esophageal cancer models. The presentations also included results from preliminary in vivo studies conducted in conjunction with collaborators at Johns Hopkins Medical which demonstrated the successful translation of CPSI’s engineering and life science development into functional systems capable of delivering of an ultra-cold, highly lethal insult (ablative dose) within a matter of minutes.

Click here to read the full press release: Presentations Feature CPSI’s FrostBite GI Cancer Cryoablation Platform

Contact us to learn more about CPSI’s Cryoablation Medical Device Research & Development Programs

View other CPSI Biotech news and recent patent announcements

post

SmartThaw Presentation Given at Cryo2016

CPSI researchers present a scientific poster on the SmartThaw™ cell thawing system.

OWEGO, NY — CPSI Biotech scientists just returned from presenting at the Society for Cryobiology Annual Meeting (Cryo2016) in Ottawa, CA (July 24-27). CPSI’s involvement included a scientific poster presentation and demonstration of CPSI’s new SmartThaw™ device designed to improve the thawing process of frozen cell and tissue products.

This scientific study on SmartThaw™ conducted by a team of researchers from CPSI and led by Dr. Kristi Snyder (Director of Operations and Principal Scientist) and Kimberly Santucci (Research Scientist). “SmartThaw™ System is a new device for controlled and rapid dry thawing of cryopreserved (frozen) samples and products. This study demonstrated that sample thawing with SmartThaw™ improves processing of frozen products while also providing equivalent, and in several cases, improved sample viability post-thaw” stated Ms. Santucci. Speaking to the technology, Dr. Snyder stated “We introduced the prototype system this spring and have been collecting end-user feedback and input for final design and performance focus. These insights have aided in the final design engineering which is now in process. As a result of these ongoing activities, we are targeting commercial launch in late Q3 2016.”

The poster titled “Assessment of SmartThaw™: A novel dry thawing system for cryopreserved cell products” focused on the improved processing and outcome that can be obtained using SmartThaw™. The poster highlighted studies conducted on CHO, PC-3, human endothelial, and mesenchymal stem cells.

Click here to read the full press release: CPSI researchers present a scientific poster on the SmartThaw™ cell thawing system.

View the Poster Presented at the Society for Cryobiology conference: Cryo 2016 Smart Thaw Poster

View other CPSI Biotech news and recent patent announcements

Chapter in “Multiscale Technologies for Cryomedicine” details the technologies and approaches used for cryoablation and features CPSI’s patented next generation Supercritical Nitrogen cryoablation device

OWEGO, NY – CPSI Biotech announced today the publication of the new medical text, Multiscale Technologies for Cryomedicine – Implementation form Nano to Macroscale, which includes a chapter authored by CPSI scientists. The chapter titled “Enhanced Cryoablative Methodologies” focuses on the various technologies, approaches and mechanisms involved in the use of cryoablation. In addition to technologies used today clinically, the chapter highlights several next generation technologies, including CPSI’s supercritical nitrogen system (SCN), which has shown promise in advancing the application of cryoablation for the treatment of numerous cancers and cardiac arrhythmias.

The text, published by World Scientific Publishing Co, was co-edited by Dr. Xiaoming He (Ohio State University) and Dr. John Bischof (University of Minnesota) and is a compilation of works by renowned researchers working in the field of cryomedicine covering topic areas ranging from cryoablation of cancer to various aspects of cell cryopreservation. When asked about the book, Dr. John M. Baust (President, CPSI Biotech and lead author on CPSI’s contribution) stated “Drs. He and Bischof should be congratulated for a superb job assembling this text. The book covers a broad array of hot topic areas in the field of Cryomedicine and should be highly valuable to a wide readership including clinicians and researchers alike.”

Multiscale Technologies for Cryomedicine, initially published online as an e-book in July, is timely in view of the growing interest in use of cryoablation for the treatment of cancer and can be accessed via the World Scientific Publishing Co website at http://www.worldscientific.com/worldscibooks/10.1142/9870

Click here to read the full press release: CPSI’s SCN Cryoablation System Highlighted in New Medical Text

View other CPSI Biotech news and recent patent announcements

post

News Segment Features CPSI’s FrostBite Cancer Treatment Device

 

Novel technology under development by CPSI offers great potential in the battle against pancreatic cancer 

OWEGO, NY – A story focusing on CPSI’s novel anti-cancer device platform recently aired on FOX40 WICZ-TV Binghamton. The segment featured CPSI’s FrostBite cryoablation technology which is designed to use freezing to target and destroy pancreatic cancer tumors. The FrostBite technology represents the first endoscopic ultrasound compatible trans-esophageal cryoablation device of its kind. The team at CPSI has developed the prototype catheter and conducted a series of pilot pre-clinical studies in conjunction with collaborators at John Hopkins Medical School.

Speaking about the technology, Dr. John Baust (President of CPSI) stated, “As pancreatic cancer is a highly lethal disease with limited treatment options available to patients, we are looking forward to taking the next steps in development in support of moving FrostBite closer to commercialization. While FrostBite is still in the R&D phase, the technology results look very promising and we hope to be able to move through the final development and testing necessary for FDA approval and commercialization.”

Click here to read the full press release: News Segment Features CPSI’s FrostBite Cancer Treatment Device

View the feature story on FOX 40 WICZ-TV Binghamton

View other CPSI Biotech news and recent patent announcements

Article published in BioProcessing Journal details how CPSI Biotech’s novel SmartThaw™ dry thawing device could revolutionize frozen sample thawing

OWEGO, NY – A peer-reviewed research article detailing the development of CPSI’s SmartThaw™ device was published in this month’s issue of BioProcessing Journal (Volume 15, Number 1; pages 30-41).  The manuscript, titled Development and Assessment of a Novel Device for the Controlled Dry Thawing of Cryopreserved Cell Products, focuses on comparative evaluations between SmartThaw™ and water bath thawing (the gold standard) using human mesenchymal stem cell (hMSC) and prostate cancer (PC-3) cell cultures and demonstrates the improvement in sample processing and quality obtained using SmartThaw™.

Click here to read the full press release: SmartThaw™ Offers a New Standard in Thawing of Cryopreserved Products

View other CPSI Biotech news and recent patent announcements

CPSI Develops New Device to Treat Esophageal and Pancreatic Cancer

April is National Esophageal Cancer awareness month, and CPSI shares in the fight to develop new therapies for esophageal cancer.

Owego, NY – In conjunction with National Esophageal Cancer awareness month, CPSI has announced the development of a next generation medical device designed to freeze cancer in situ (in place within the body), thereby destroying the tumor.  CPSI’s SCN Platform has the potential to revolutionize the treatment of diseases ranging from pancreatic cancer, Barrett’s esophagus and esophageal cancer to cardiac arrhythmias, potentially impacting millions of patients annually worldwide.  The SCN device converts liquid nitrogen (LN2) to Supercritical Nitrogen (SCN) then, using a minimally invasive approach, delivers the cryogen via specialized cryoprobes to freeze a targeted tissue.  CPSI, in conjunction with collaborators at Johns Hopkins Medical, have conducted a series of preliminary studies demonstrating the successful delivery of an ultra-cold (<-170°C), highly effective lethal insult (ablative dose) within a matter of minutes.  Continued research and development efforts in esophageal cancer are also supported by a grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program. With these results, the team is now focused on development of the SCN Platform for the treatment of several gastroenterological diseases, including esophageal and pancreatic cancer.

Click here to read the full press release: CPSI’s SCN cryoablation technology platform will provide an advanced, cost effective, minimally invasive treatment strategy for pancreatic, esophageal and other gastroenterological cancers.

View other CPSI Biotech news and recent patent announcements

 

CPSI and Eppendorf release white paper on cryopreservation sample storage quality

OWEGO, NY – CPSI Biotech announced today the recent publication of a scientific white paper discussing the impact of handling processes on sample quality following cryopreservation. The white paper titled, “Biopreservation: The impact of freezing and cold storage on sample quality” (Eppendorf, White Paper No. 031) was written by Dr. John M. Baust (President and Lead Scientist, CPSI Biotech) at the request of Eppendorf’s technical team in response to growing requests by clients for more information related to the impact of storage temperature and the handling of samples prior to, during and following preservation.

View the Full Press release here: Scientific article focuses on improving sample quality following storage

Joint white paper effort by CPSI and Eppendorf highlights the impact of handling and storage on sample quality following cryopreservation. (view this press release on Digital Journal)

View other CPSI Biotech news and recent patent announcements

post

SmartThaw Featured at ISBiotech

OWEGO, NY — CPSI Biotech scientists just returned from presenting and exhibiting at the 2016 ISBiotech 6th Annual Spring Meeting in Washington, DC (March 7-9). CPSI’s involvement included a corporate exhibit, highlighted by the pre-sales launch of SmartThaw dry thawing system, and a scientific presentation on cell cryopreservation and next generation devices designed to improve the freezing and thawing process.

Click here to view the entire press release: SmartThaw Featured at ISBiotech Spring Meeting with CPSI Exhibit and Presentation

View other CPSI Biotech news and recent patent announcements

CPSI Issued US Patent for ASSIST

OWEGO, NY — CPSI Biotech announced today the issuance of a patent by the US Patent Office covering the design and method of use of a new tissue engineered model (TEM) for utilization in research and development activities. Referred to as the ASSIST™ system, TEM is designed as a laboratory-based in vivo like 3-dimentional tissue substitute for animal testing. ASSIST™ can be formulated to contain any number of human, animal or other cell types which can be cultured to form a robust 3-D tissue structure.

Click here to view the entire press release: US Patent Issued on CPSI’s Engineered Tissue Model Platform

View other CPSI Biotech news and recent patent announcements

Two US Patents Issued on the Supercritical Nitrogen (SCN) Cryoablation Platform

OWEGO, NY — CPSI Biotech announced today the issuance of two new patents by the US Patent Office covering device design and method of use for the supercritical nitrogen (SCN) cryoablation medical device platform. CPSI has invested the last 6+ years on the development and testing of this next generation cryoablation device platform.
The patents (US Pat#’s: 9,089,316 and 8,998,888) include design and use of the advanced SCN cryogenic medical system which offers promise for utilization in the clinical arena. CPSI completed a technology transfer agreement involving the SCN platform in 2012 under which CPSI retained exclusive license rights for development and commercialization of the SCN technology platform in a number of areas, including pancreatic cancer and cardiac arrhythmias. CPSI is currently pursuing the acquisition of financing to support final development, testing and obtaining regulatory approval in support of commercialization.
Latest Patents Cover Device Design and Method of Use for the Next Generation Super-critical Nitrogen Cryoablation Device Platform (Press Release, December 21, 2015)
Read the full press release here